US Biopharmaceuticals: Revisiting the menins: BrandImpact trends favorable ahead of encouraging EHA/ASCO

Research evidence excerpt

US Biopharmaceuticals: Revisiting the menins: BrandImpact trends favorable ahead of encouraging EHA/ASCO

Accessible version

US Biopharmaceuticals

Revisiting the menins: BrandImpact trends

favorable ahead of encouraging EHA/ASCO

Industry Overview

Signals remain favorable ahead of ASCO/ EHA updates 21 May 2026

Despite reporting solid sequential growth for their respective menin inhibitors, shares of Equity

both Syndax (Revuforj) and Kura (Komzifti) traded lower following 1Q earnings. At a high United States

level, we’re not surprised. While the rival launches in R/R NPM1m AML are early, we think Biopharmaceuticals

the intensity of the debate left investors looking for more evidence of momentum (see Jason Zemansky

our 1Q preview). With ASCO and EHA offering another wave of incremental clinical Research Analyst

updates, we reassess the landscape leveraging the latest BrandImpact data. Ultimately, BofAS+1 646 855 4280

while we continue to see both names as well positioned, the competitive balance of the jason.zemansky@bofa.com

two launches remains far from settled. Still, with both names trading with little value, in Jacqueline Plesset

Research Analyst

our view, for the opportunity, maintain Buy and $30 PO for Kura and $29 PO for Syndax. BofAS

+1 646 855 0014

ASCO/ EHA: Incremental updates may still help expand use jacqueline.plesset@bofa.com

Ahead of ASCO (May 29–June 2) and EHA (June 11–14), we spoke with our KOLs to

review Kura and Syndax’s presentations. While viewing the updates as incremental— Abbreviations:

largely centered on longer-term follow-ups and real-world data—our experts still saw 2L: second-line

them as relevant, offering another opportunity to shape perceptions and support broader

AML: acute myeloid leukemianear-term use ahead of more definitive readouts.